Incidence of Clostridium difficile infection in patients receiving high-risk antibiotics with or without a proton pump inhibitor

Journal of Hospital Infection

Volumn 92, Issue 2, 2016, Pages 173-177

  Gordon, D ^a   Young, L R ^a   Reddy, S ^b   Bergman, C ^a   Young, J D ^c  

^a JESSE BROWN VA MEDICAL CENTER   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Clostridium difficile; Healthcare associated diarrhoea; Proton pump inhibitor

Indexed keywords

ANTIBIOTIC AGENT; CEFIXIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; CLINDAMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT;

AGED; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL FEATURE; CLOSTRIDIUM DIFFICILE INFECTION; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG CHOICE; DRUG EXPOSURE; DRUG SAFETY; FEMALE; HIGH RISK POPULATION; HUMAN; INFECTION SENSITIVITY; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; OSTEOMYELITIS; OUTCOME ASSESSMENT; PNEUMONIA; PRESCRIPTION; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; SKIN INFECTION; TREATMENT DURATION; URINARY TRACT INFECTION; VETERAN; ADOLESCENT; ADULT; CLASSIFICATION; CLOSTRIDIUM INFECTIONS; CROSS INFECTION; DIARRHEA; GENETICS; INCIDENCE; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; PEPTOCLOSTRIDIUM DIFFICILE; RISK ASSESSMENT; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; CROSS INFECTION; DIARRHEA; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROTON PUMP INHIBITORS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; YOUNG ADULT;

EID: 84958059611     PISSN: 01956701     EISSN: 15322939     Source Type: Journal    
DOI: 10.1016/j.jhin.2015.10.009     Document Type: Article

References (35)

1. Blossom D.B., McDonald L.C. The challenges posed by reemerging Clostridium difficile infection. Clin Infect Dis 2007, 45:222-227.
2. Key C.P., LaMont J.T. Clostridium difficile - more difficult than ever. N Engl J Med 2008, 359:1932-1940.
3. He M., Miyajima F., Roberts P., et al. Emergence and global spread of epidemic healthcare-associated Clostridium difficile. Nat Genet 2013, 45:109-113.
4. Pépin J., Valiquette L., Cossette B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. Can Med Assoc J 2005, 73:1037-1042.
5. Kyne L., Hamel M.B., Polavaram R., Kelly C.P. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 2002, 34:346-353.
6. Bartlett J.G., Moon N., Chang T.W., Taylor N., Onderdonk A.B. Role of Clostridium difficile in antibiotic-associated pseudomembranous colitis. Gastroenterology 1978, 75:778-782.
7. Pépin J., Saheb N., Coulombe M.A., et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005, 41:1254-1260.
8. Deshpande A., Pasupuleti V., Thota P., et al. Community-associated Clostridium difficile infection and antibiotics: a meta-analysis. J Antimicrob Chemother 2013, 68:1951-1961.
9. Brown K.A., Khanafer N., Daneman N., Fisman D.N. Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection. Antimicrob Agents Chemother 2013, 57:2326-2332.
10. Gurian L., Ward T.T., Katon R.M. Possible foodborne transmission in a case of pseudomembranous colitis due to Clostridium difficile infection. Gastroenterology 1982, 83:465-469.
11. Tennant S.M., Heartland E.L., Phumoonna T., et al. Influence of gastric acid on susceptibility to infection with ingested bacterial pathogens. Infect Immun 2008, 76:639-645.
12. Cunningham R., Mustoe E., Spiller L., Lewis S., Benjamin N. Acidified nitrite: a host defence against colonization with C. difficile spores?. J Hosp Infect 2014, 86:155-157.
13. Dial S., Delaney J.A., Barkun A.N., Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005, 294:2989-2995.
14. Dial S., Delaney J.A., Schneider V., Suissa S. Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy. Can Med Assoc J 2006, 175:745-748.
15. Linsky A., Gupta K., Lawler E.V., Fonda J.R., Hermos J.A. Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Archs Intern Med 2010, 170:772-778.
16. Howell M.D., Novack V., Grgurich P., et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Archs Intern Med 2010, 170:784-790.
17. Morrison R.H., Hall N.S., Said M., et al. Risk factors associated with complications and mortality in patients with Clostridium difficile infection. Clin Infect Dis 2011, 53:1173-1178.
18. Kwok C.S., Arthur A.K., Anibueze C.I., Singh S., Cavallazzi R., Loke Y.K. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol 2012, 107:1011-1019.
19. Janarthanan S., Ditah I., Adler D.G., Ehrinpreis M.N. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gasteroenterol 2012, 107:1001-1010.
20. US Food and Drug Administration, Drug Safety Communication. Clostridium difficile-associated diarrhea can be associated with stomach acid drugs known as proton pump inhibitors (PPIs). February 8th, 2012. Available at: [last accessed March 2015]. http://www.fda.gov/drugs/drugsafety/ucm290510.htm.
21. Beaulieu M., Williamson D., Pichette G., Lachaine J. Risk of Clostridium difficile-associated disease among patients receiving proton pump inhibitors in a Quebec medical intensive care unit. Infect Control Hosp Epidemiol 2007, 28:1305-1307.
22. Naggie S., Miller B.A., Zuzak K.B., et al. A case-control study of community-onset Clostridium difficile infection: no role for proton pump inhibitors. Am J Med 2011, 124:276e1-276e7.
23. Fellmeth G., Yarlagadda S., Iyer S. Epidemiology of community-onset Clostridium difficile infection in a community in the South of England. J Infect Public Health 2010, 3:118-123.
24. Freedberg D.E., Salmasian H., Friedman C., Abrams J.A. Proton pump inhibitors and risk for recurrent Clostridium difficile infection among inpatients. Am J Gastroenterol 2013, 108:1794-1801.
25. Loo V.G., Poirier L., Miller M.A., et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005, 353:2442-2449.
26. Pepin J., Alary M.E., Valiquette L., et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005, 40:1591-1597.
27. Dalton B.R., Lye-Maccannell T., Henderson E.A., Maccannell D.R., Louie T.J. Proton pump inhibitors significantly increase the risk of Clostridium difficile infection in a low-endemicity, non-outbreak hospital setting. Aliment Pharmacol Ther 2009, 29:626-634.
28. Shah S., Lewis A., Leopold D., et al. Gastric acid suppression does not promote clostridial diarrhoea in the elderly. Q J Med 2000, 93:175-181.
29. Debast S.B., Bauer M.P., Kuijper E.J. European Society of Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 2014, 20:1-26.
30. Cohen S.H., Gerding D.N., Johnson S., et al. Clinical guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010, 31:431-455.
31. Tang-Feldman Y., Mayo S., Silva J., Cohen S. Molecular analysis of Clostridium difficile strains isolated from 18 cases of recurrent Clostridium difficile-associated diarrhea. J Clin Microbiol 2003, 41:3413-3414.
32. McDonald E.G., Milligan J., Frenette C., Lee T.C. Continuous proton pump inhibitor therapy and the associated risk of recurrent Clostridium difficile infection. JAMA Intern Med 2015, 175:784-791.
33. Barletta J.F., Kanji S., MacLaren R., Lat I., Erstad B.L. Pharmacoepidemiology of stress ulcer prophylaxis in the United States and Canada. J Crit Care 2014, 29:955-960.
34. Heidelbaugh J.J., Goldberg K.L., Inadomi J.M. Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk. Am J Gastroenterol 2009, 104(Suppl. 2):S27-32.
35. Inadomi M.J., McIntyre L., Bernard L., et al. Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs. Am J Gastroenterol 2003, 98:1940-1944.